



27 June 2013

ASX RELEASE

Publication of Explanatory Notice for shareholders who hold stock in MEIP

Novogen Ltd today announces the publication of an Explanatory Notice for its shareholders who hold stock in MEI Pharma Inc (MEIP).

Up till November 2012, NASDAQ-listed and US-based biotechnology company, MEIP, was a partly-owned subsidiary of Novogen Ltd. At that time, Novogen received shareholder approval to divest itself of its shareholding in MEIP through an *in specie* share distribution, with Novogen shareholders receiving a proportional allocation of MEIP stock.

For many Australian and New Zealand shareholders, we understand that the complexities of holding and selling US-listed shares, particularly where those shareholdings involve unmarketable parcels of stock, have been challenging. Novogen believes that many of its shareholders who have small holdings in MEIP would benefit from a guidance note which deals with some issues arising from holding foreign stock, particularly in relation to tax implications and, if desired, cost-effective means of selling the stock.

Dr Graham Kelly, Novogen Chairman and CEO, said, "Preparing this Guidance document has been a large and time-consuming project that was taken on by our Deputy Chairman, Robert Birch. I cannot emphasise too much that what we have provided in this document is a general guide designed to assist and we hope clarify the situation for Novogen shareholders who hold MEIP stock. **It is not in any way advice** and we cannot accept any responsibility for it. This guide reinforces that care needs to be taken and does not replace getting your own advice from a qualified expert, particularly in relation to tax. We do hope though that our shareholders find it useful."

The Explanatory Notice is published on the Company's website under the 'Shareholders' menu ('MEIP in specie distribution') or may be downloaded at <http://novogen.com/shareholder-guide-selling-us-shares-2/>.

About Novogen

Novogen Ltd is a public Australian biotechnology company whose shares trade on both the Australian Stock Exchange (symbol 'NRT') and NASDAQ (symbol 'NVGN'). The Company is based in Sydney, Australia and is focused on the development of a family of novel anti-cancer drugs based on comprehensive anti-cancer activity against both cancer cells and cancer stem cells. The Company's inaugural drug candidate is CS-6.

About CS-6

CS-6 belongs to a new class of drug candidates intended to treat most forms of cancer in a comprehensive manner, targeting both cancer cells and their progenitor cells, cancer stem cells. CS-6 shows broad anti-proliferative and cytotoxic activity against human cancer cells and ovarian cancer stem cells. CS-6 also has been designed deliberately to meet the major known criteria for crossing the blood-brain barrier, and for that reason is being developed as a first-line for the treatment of glioblastoma multiforme, the main form of primary brain cancer.

Further information

Contact Dr Graham Kelly, Chief Executive Officer.

Tel: 61 2 9476 0344

Fax: 61 2 9476 0388

Mobile: (61) 0429 854 390

16-20 Edgeworth David Ave Hornsby NSW 2077 AUSTRALIA

PO Box 2333 Hornsby Westfield NSW 1635 AUSTRALIA

E: Graham.Kelly@novogen.com

Further information is available on the Company's web site, www.novogen.com